Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Recruiting now · Phase 3

Conditions studied: Moderate-to-severe Chronic Plaque Psoriasis

In brief

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Key facts

Study ID

NCT07362017

Run by

Vanda Pharmaceuticals

People needed

300

Starts

2026-02-17

Expected to finish

2028-12-01

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects aged 18-65 years, inclusive
• BMI >18 and <40
• Minimum affected BSA of 10%
• PASI score ≥ 12
• PGA ≥ 3
• Diagnosed with moderate-to-severe plaque psoriasis

You may not qualify if…

• Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
• History of an allergic reaction or known and/or significant sensitivity to study drug

Where it is running

• Vanda Investigational Site — Glendale, Arizona, United States (enrolling)
• Vanda Investigational Site — Fremont, California, United States (enrolling)
• Vanda Investigational Site — Rochester, New York, United States (enrolling)
• Vanda Investigational Site — Spokane, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.